Neuroinflammation plays a critical role in the neurologic decline of ICH patients. Ir-CPI, the lead drug candidate of this program, exhibits a unique mechanism of action by targeting coagulation factors (FXIIa & FXIa) and neutrophils, key driver components of the neuroinflammatory process. Ir-CPI prevents blood clot formation without increasing the bleeding risk — a major asset in ICH patients — due to the specific coagulation factors targeted by this compound.

In parallel, Bioxodes is developing a pipeline of drug candidates with the objectives to treat chronic thrombo-inflammatory and inflammatory diseases. The goal is to leverage the activity of Ir-CPI against neutrophil activation and neutrophil extracellular trap (NET) formation.